{"id":"23fd0c7f63f1","type":"article","url":"https://hartvaat.nl/2026/02/16/nieuwe-plasma-eiwitbiomarkers-en-risico-op-veneuze-trombo-embolie/","title":"Nieuwe plasma-eiwitbiomarkers en risico op veneuze trombo-embolie","title_en":"Novel Plasma Proteomic Markers and Risk of Venous Thromboembolism","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":["biomarkers-cardiovasculair","trombocytenaggregatieremmers","trombose","veneuze-trombose"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.074493","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.074493","authors":["Weihong Tang"],"significance":7,"published":"2026-02-16","source_date":"2026-02-16","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This Circulation study used large-scale, high-throughput proteomics to identify novel plasma protein markers associated with venous thromboembolism risk, advancing the molecular understanding of VTE pathogenesis.","created":"2026-07-03T10:25:21Z","updated":"2026-07-03T13:24:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Veneuze trombo-embolie is een belangrijke cardiovasculaire aandoening waarvan de etiologie onvolledig begrepen is. Met grootschalige aptameer-gebaseerde proteomics werden nieuwe circulerende eiwitbiomarkers en biologische routes geïdentificeerd die het VTE-risico beïnvloeden.","abstract_original":"BACKGROUND:Venous thromboembolism (VTE) is a leading cardiovascular disease, yet its etiology is incompletely understood. This study used large-scale, high-throughput aptamer-based proteomics to identify new circulating protein biomarkers and biological pathways for incident VTE.METHODS:We included 4 longitudinal cohorts (the ARIC study [Atherosclerosis Risk in Communities], CHS [Cardiovascular Health Study], MESA [Multi-Ethnic Study of Atherosclerosis], and the HUNT study [Trøndelag Health]) that identified 1371 incident noncancer VTEs among 20 737 participants followed for a maximum of 10 to 29 years. We used the SomaScan to measure baseline plasma levels of ≈5000 to 7000 proteins and examined the prospective relationships between the protein biomarkers and noncancer VTE. We then conducted an external replication of top VTE proteins in 783 incident noncancer VTEs among 39 097 participants in the UKB study (UK Biobank) based on the Olink proteomics platform. We used Cox proportional h"}